Olaparib treatment in advanced breast or ovarian cancer patients with BRCA1/2 germline mutations showed a 41% and a 33% objective response rate defined as the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period (Table 2; Audeh et al. 2010; Tutt et al. 2010). The gene discussed is BRCA1; the disease is neoplasm.